Webinar: Discover How Virtual Twin Experiences Add Value in Life Sciences Manufacturing

© poba/Getty Images
© poba/Getty Images

Life Sciences industry is undergoing a fundamental shift, driven by new technologies, e.g. personalized medicines, digital health, continuous processes, as well as the drive to lower healthcare cost and changes in re-imbursement to a value-based pricing model.

Digitalization is instrumental in facilitating a successful transformation to a flexible, agile and cost-effective pharma manufacturing. Virtual twins can significantly improve the quality and efficiency of projects in engineering and commissioning as well as help improve performance during operations and maintenance.

 

Discover How Virtual Twin Experiences Add Value in Life Sciences Manufacturing
March 26, 2020 | 10.00 a.m. (CET)

           

Join this webinar to:

  • Understand the current industry challenges and the limitations of current approaches
  • Discover how using a virtual twin approach can bring value
  • Learn from practical experiences

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.